Nuvation Bio Reports Third Quarter 2026 Financial Results and Provides Business Update
PR Newswire•04/11/2026•16:05 ET
0
Key Highlights
- ➤Q3 total revenue $45.0 million, including $27.5 million IBTROZI net product revenue
- ➤IBTROZI net product revenue increased 18% quarter-over-quarter
- ➤FDA-approved sNDA updates IBTROZI median response duration to 49.7 months
- ➤FDA granted Fast Track Designation to safusidenib for IDH1-mutant glioma
- ➤Cash, cash equivalents, and marketable securities totaled $663.4 million September 30
Expert Statements
David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio
“Just over one year after launch, IBTROZI was established as the market leader in advanced ROS1+ NSCLC, for both new patient starts and active patients across all lines of therapy combined, based on IQVIA claims data”
David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio
“Our rapid rise to market leadership reflects growing provider confidence in IBTROZI's durability of more than four years in TKI-naïve patients and a generally favorable safety profile that helps patients stay on therapy. With our recent sNDA approval, the label now reflects IBTROZI's 49.7-month median duration of response in TRUST-I, giving physicians clear data to guide treatment decisions and supporting its use early in a patient's care.”
David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio
“The FDA's recent Fast Track Designation for safusidenib underscores both the significant unmet need in IDH1-mutant glioma and the potential of this investigational medicine to address it. We are moving quickly to advance our comprehensive development program, with two Phase 2 and two pivotal Phase 3 studies spanning multiple IDH1-mutant glioma subpopulations, designed to reach a broad spectrum of patients with this disease.”
Nuvation Bio Reports Third Quarter 2026 Financial Results and Provides Business Update PR Newswire
Achieved $45.0 million in third quarter 2026 total revenue, including $27.5 million in net product revenue for IBTROZI(®) (taletrectinib)
Get started
Create a free account to read the full story.